Vistor
Track this competitor Create a free account to be notified when it wins a contract.
- Contracts won
- 6
- Period
- 3 September 2026 – 16 September 2026
Its main clients
- Landspítali Háskólasjúkrahús · 6 contracts
Where and what
Supplies · 6
Its contracts coming to an end
So many opportunities to take over these contracts when they are re-tendered.
| Planned end | Contract | Current holder | Amount |
|---|---|---|---|
| 22 July 2027 re-tender around January 2027 |
Ýmis lyf 79 Ýmsir ATC flokkar
Landspítali Háskólasjúkrahús framework agreement |
Icepharma Vistor Alvogen ehf Icepharma Pfizer Teva Pharma Iceland ehf 12 bids received |
– |
| 29 August 2027 re-tender around March 2027 |
Ýmis lyf 78 - MS lyf
Landspítali Háskólasjúkrahús framework agreement |
Lyfjaver ehf Icepharma Vistor Alvogen ehf 12 bids received |
– |
| 16 January 2028 re-tender around July 2027 |
Ýmis lyf 80 Æxlishemjandi lyf
Landspítali Háskólasjúkrahús framework agreement |
Vistor Icepharma Icepharma Pfizer Williams & Halls ehf Alvogen ehf 29 bids received |
– |
| 9 June 2028 re-tender around December 2027 |
Ýmis lyf 87 Immúnoglóbúlín
Landspítali Háskólasjúkrahús |
Icepharma Alvogen ehf Vistor 5 bids received |
– |
| 2 July 2029 re-tender around January 2029 |
Ýmis lyf 77
Landspítali Háskólasjúkrahús framework agreement |
Vistor 1 bid received |
– |
Contracts won
| Date | Contract | Buyer | Amount |
|---|---|---|---|
| 16/09/2026 | Ýmis lyf 77 | Landspítali Háskólasjúkrahús | – |
| 15/09/2026 | Ýmis lyf 80 Æxlishemjandi lyf | Landspítali Háskólasjúkrahús | – |
| 15/09/2026 | Ýmis lyf 79 Ýmsir ATC flokkar | Landspítali Háskólasjúkrahús | – |
| 11/09/2026 | Ýmis lyf 88 - Ýmsir ATC flokkar | Landspítali Háskólasjúkrahús | – |
| 11/09/2026 | Ýmis lyf 87 Immúnoglóbúlín | Landspítali Háskólasjúkrahús | – |
| 03/09/2026 | Ýmis lyf 78 - MS lyf | Landspítali Háskólasjúkrahús | – |
Source: contract award notices published on TED (Publications Office of the European Union), above the EU thresholds. Contracts published only in Belgium are not included yet.